SHARES of medical technology company Biolidics slumped on their trading debut on the Catalist board, with the stock closing down 16 per cent from its listing price of S$0.28.

SINGAPORE (Dec 19): Just two hours into its debut on the Singapore Exchange (SGX) Catalist board, shares in medical technology firm Biolidics have slumped 23.2% from its listing price of 28 cents. The stock on Wednesday opened 5.4% lower than its IPO price at 26.5 cents. As at 11.15am, Biolidics is...

SHARES of medical technology company Biolidics opened below its IPO (initial public offering) price on its Catalist debut on Wednesday, with the stock opening at S$0.265, down 5.4 per cent from its listing price of S$0.28.

The company seeks to use its public-listing status to expand its clinical services applications and customer segment. The post Medical tech firm Biolidics set for SGX Catalist debut appeared first on DealStreetAsia.

MEDICAL technology company Biolidics on Tuesday launched an initial public offering (IPO) of 27.5 million new shares at S$0.28 each. The placement is in conjunction with its proposed listing on the Catalist board on Dec 19.

SINGAPORE (Dec 11): Medtech company Biolidics is selling 27.5 million new shares at 28 cents each to retail and institutional investors in conjunction with its proposed listing on the Catalist Board of the Singapore Exchange. See: Clearbridge Health associate Biolidics lodges prelim prospectus Inco...

MEDICAL technology firm Biolidics Limited, a cancer diagnostic solutions developer formerly known as Clearbridge Biomedics, lodged a preliminary prospectus on Friday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.

SINGAPORE (Nov 26): Biolidics, a cancer diagnostic solutions developer and an associate company of Clearbridge Health, on Friday lodged a preliminary prospectus for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board. Biolidics, incorporated as Clearbridge Biomedics i...

MEDICAL technology firm Biolidics Limited, a cancer diagnostic solutions developer formerly known as Clearbridge Biomedics, lodged a preliminary prospectus on Friday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.